Emerging studies suggest this peptide, a dual agonist targeting both incretin and another hormone, may represent a significant development for weight management . Preliminary patient trials have indicated impressive decreases in visceral mass , possibly surpassing existing obesity treatments. Despite this, additional study is necessary to thoroughl